3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Advanced Breast Cancer
1
Interventions
Fulvestrant
6
olaparib
4
Letrozole
4
trastuzumab deruxtecan
3
Aromatase Inhibitors
3
Anastrozole
3
sacituzumab govitecan
2
pyrotinib
2
eribulin
2
dalpiciclib
2
Paclitaxel
2
Goserelin
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Capecitabine
2
toripalimab
1
talazoparib
1
sonidegib
1
ribociclib
1
pembrolizumab
1
neratinib
1
liposomal doxorubicin
1
elacestrant
1
disitamab vedotin
1
ceralasertib
1
capivasertib
1
balixafortide
1
apatinib
1
abemaciclib
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Breast Cancer
×
balixafortide
×
Clear all
NCT04826016
2023-03-20
POLTER
MedSIR
Phase 1/2
Withdrawn